DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Rivoglitazone
Rivoglitazone
CDR Clinical Review Report for Soliqua
Comparison of Clinical Outcomes and Adverse Events Associated with Glucose-Lowering Drugs in Patients with Type 2 Diabetes: a Meta-Analysis
Modifications to the Harmonized Tariff Schedule of the United States To
Comparative Safety and Effectiveness of Type 2 Diabetes Medicines Final Report September 2014
The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
Pharmaceuticals Compositions Comprising Sulphonylurea-Class Insulin Secretagogue and Polyethylene Glycol Castor Oil
Curriculum Vitae
Possible Role of Rivoglitazone Thiazolidine Class of Drug As Dual
Design, Synthesis, and Evaluation of Thiazolidinedione Derivatives Inhibiting Bcl-2/Bcl-Xl Or Ablating Androgen Receptor for the Treatment of Prostate Cancer
Canagliflozin, Dapagliflozin and Empagliflozin Monotherapy for Treating Type 2 Diabetes: Systematic Review and Economic Evaluation
(12) United States Patent (10) Patent No.: US 9,492.422 B2 Takahashi Et Al
395 B 536 Winstal. O. Saito EEEEEE
REVIEW Thyroid Hormone Receptors Regulate Adipogenesis And
Downloaded January 26, 2009, from Betic Animal Model
Stembook 2018.Pdf
Report Synopsis for CS0011-A-U301
Diabetes Europe 2018: in Vivo Assessment of Thiazolidinedione Subsidiaries As Euglycemic Specialists- Diana Aleman- National Polytechnic Institute
Top View
2020 Diabetes Guideline Data Supplement
Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
(12) Patent Application Publication (10) Pub. No.: US 2010/0179131 A1 Klein Et Al
The Role of Peroxisome Proliferator-Activated Receptor in the Treatment of Non-Alcoholic Fatty Liver Disease
Chembl an Open Data Resource of Medicinal Chemistry and Patent Data John P
Excluded Studies
Pharmaabkommen A1 E
Appendix: NMA of Comparative Efficacy of Semaglutide to SGLT-2Is in Patients Inadequately Controlled on 1-2 Oads
Favorable Cardiovascular Effects of Pioglitazone: a Meta-Analysis
Canagliflozin, Dapagliflozin and Empagliflozin Monotherapy for Treating Type 2 Diabetes : Systematic Review and Economic Evaluation
Report Synopsis CS0011-A-U302
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Canagliflozin, Dapagliflozin and Empagliflozin Monotherapy for Treating Type 2 Diabetes
WO 2015/071889 Al 21 May 2015 (21.05.2015) P O P C T
Pleiotropic Effects of Glitazones: a Double Edge Sword?
Review Article
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Recent Advances in Diabetes Mellitus
NDO Home | Contact | Register for NDO Access
Biocatalyzed Synthesis of Antidiabetic Drugs: a Review
Sulphonylurea, Metformin, Tzds: Potential Drugs to Cure Diabetes
2012/045863 Al
An Overview on Newer Antidiabetic Agents
Identification and Characterization of Antidiabetic And
Appendix L: Excluded Studies
The Journey of Thiazolidinediones As Modulators of Ppars for the Management of Diabetes: a Critical Review
Statins, Fibrates, Thiazolidinediones and Resveratrol As Adjunctive Therapies in Sepsis: Could Mitochondria Be a Common Target? Jerome Morel1 and Mervyn Singer2*
New Drugs in Development for the Treatment of Diabetes
WO 2017/198177 Al 23 November 2017 (23.11.2017) W !P O PCT